Scarica l'app Stockscreener
1.37
4.86%
-0.07
Dopo l'orario di chiusura:
1.86
0.49
+35.77%
Precedente Chiudi:
$1.44
Aprire:
$1.43
Volume 24 ore:
1.16M
Relative Volume:
4.51
Capitalizzazione di mercato:
$20.52M
Reddito:
$1.16M
Utile/perdita netta:
$-12.02M
Rapporto P/E:
-1.3197
EPS:
-1.0381
Flusso di cassa netto:
$-10.16M
1 W Prestazione:
+3.01%
1M Prestazione:
-34.45%
6M Prestazione:
-19.41%
1 anno Prestazione:
-35.07%
Intervallo 1D:
$1.31
$1.4572
Intervallo di 1 settimana:
$1.31
$1.4675
Portata 52W:
$1.13
$3.78
Dare Bioscience Inc Stock (DARE) Company Profile
Nome
Dare Bioscience Inc
Settore
Industria
Telefono
858-926-7655
Indirizzo
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
1.37 | 21.57M | 1.16M | -12.02M | -10.16M | -1.0381 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dare Bioscience Inc Borsa (DARE) Ultime notizie
Dare Bioscience Q2 Results: Net loss narrows to $3.0M, cash falls - scanx.trade
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances - The Manila Times
Daré Bioscience launches Flora Sync, its first directly commercialized product - Stock Titan
Dare Bioscience Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Transcript : Daré Bioscience, Inc.Special Call - marketscreener.com
Dare Bioscience Inc (DARE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dare Bioscience (DARE.US) will release its earnings report after market close on August 13. - Moomoo
Dare Bioscience (DARE) Eases 0.75% to $1.33: Stock Hovers Between Key Support and ResistanceHedge Fund Exposure - dars.gov.et
Daré Bioscience to Host Second Quarter 2026 Financial - GlobeNewswire
Dare Bioscience Inc (DARE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dare Slides on MyMenopauseRx Hookup - Baystreet.ca
Daré Bioscience partners with menopause telehealth platform By Investing.com - Investing.com Nigeria
Daré Bioscience partners with menopause telehealth platform - Investing.com
Daré Bioscience Expands Access Options for DARE to PLAY™ - GlobeNewswire
Daré Bioscience partners with MyMenopauseRx to ... - pluang.com
DARE|Dare Bioscience Inc|Price:1.330|Chg%:+0.050 - TradingKey
Dare Bioscience Inc (DARE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dare Bioscience, Inc. Revenue Breakdown – NASDAQ:DARE - TradingView
Dare Bioscience Inc (DARE) Income Statement - TradingKey
Dare Bioscience Inc (DARE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dare Bioscience Inc (DARE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dare Bioscience Inc (DARE) Cash Flow - TradingKey
Dare Bioscience Inc (DARE) Institutional Confidence - TradingKey
Dare Bioscience Market Sentiment - Benzinga España
DARE|Dare Bioscience Inc|Price:1.280|Chg%:+0.020 - TradingKey
Daré Bioscience Releases New Investor Corporate Presentation - TipRanks
Dare Bioscience Inc (DARE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st
Daré Bioscience launches virtual bus tour webin... - Pluang
Daré Bioscience Launches “Across the U.S.” Virtual Bus Tour Webinar Series for Investors - Quiver Quantitative
Daré Bioscience Launches Nationwide Virtual Bus Tour - GlobeNewswire
Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities - The Manila Times
Daré Bioscience Files 8-K Notice of Delisting or Failure to Satisfy Nasdaq Listing Requirements – July 2026 - Minichart
Daré Bioscience Faces Nasdaq Listing Compliance Challenges - TipRanks
Dare Bioscience Received Notice of Delisting - TradingView
Daré Bioscience Advances DARE-HPV Trial, Raising New Questions for HPV Treatment Investors - TipRanks
Dare Bioscience (DARE) Shares Decline 3.38% as Stock Holds Above Key Support at $1.9BPI Bear Correction - dars.gov.et
Daré Bioscience at Virtual Investor Closing Bell: shift to sales By Investing.com - Investing.com Canada
DARE: Commercial launches and clinical milestones in women's health drive growth and value through 2027 - TradingView
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025 - 富途牛牛
Daré Bioscience Updates Investors With New Presentation - TipRanks
[8-K] Dare Bioscience, Inc. Reports Material Event - Stock Titan
Dare Bioscience Company Profile & Introduction - Moomoo
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event - The Manila Times
Price to sales forward of Dare Bioscience, Inc. – NASDAQ:DARE - TradingView
DARE Technical Analysis & Stock Price Forecast - Intellectia AI
Daré Bioscience launches prescription-free vaginal probiotic capsule for microbiome support - Contemporary OB/GYN
Price to earnings forward of Dare Bioscience, Inc. – NASDAQ:DARE - TradingView
Dare Bioscience (DARE) director receives 23,696 RSUs in lieu of cash pay - Stock Titan
Dare Bioscience (DARE) director awarded 30,805 RSUs as board compensation - Stock Titan
Dare Bioscience (DARE) grants 38,862 RSUs to board director - Stock Titan
Dare Bioscience Inc Azioni (DARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.03%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):